What Mannkind needs to do

[olebob1]

Mar 10, 2018 18:51:29 GMT -5 digger said:

Mar 10, 2018 13:00:44 GMT -5 kc said:

Happened to see this article to day about Sanofi and their problem selling their wonder drug cholesterol-lowering drug Praluent.  That is the same drug they had the lawsuit with Amgen on and lost.   But if you read the article you will see that one of the issues that both Sanofi and Amgen have with the drug is the cost to the payer (insurer)  Its way too high and they push back on letting patients receive it.    So they have worked on a new Strategy to lower the price to the payer and create a more outcome based prescribing model. 

"Now Regeneron and Sanofi are going one step further, agreeing to lower the price for Praluent to match an independent analysis that found it would be cost-effective for the highest-risk patients at a net cost of $4,500 to $8,000 a year. The companies added one condition to the lower price: that health insurers agree to remove the restrictions, like extensive tests and paperwork, that make prescribing the medicine an arduous process for doctors.

“We have to get the whole world to realize this is cost-effective for society and we have to get this drug to the patients who will benefit the most,” said George Yancopoulos, chief scientific officer at Tarrytown, New York-based Regeneron.

www.bloombergquint.com/business/2018/03/10/regeneron-sanofi-cut-heart-drug-s-price-as-trial-disappoints

This is probably the same direction that MannKind HAS to take to become a preferred Insulin product as the Healthcare industry is changing rapidly.   I have to just wonder if Mike C knew this in hiring of Dr. David Kendall.  MannKind has to work with payers to show Afrezza is the most cost effective Insulin product at either today's cost or a negotiated fixed price cost to the payer in order to gain critical mass.  Remove restrictions and make it easier to prescribe Afrezza and we will give you more cost effective pricing. Perhaps a subscription based program. 

Payers are adding the term OUTCOME BASED SOLUTIONS to their talking points and it evident as you see some of the recent marriages. 

CVS Buying Aetna

Cigna Buy Express Scripts. 

Berkshire Hathaway/Amazon / JP Morgan  Healthcare joint venture. 

Payers want good outcomes for patients at a cheaper prices.   

I would say that payers want to make money -- as much money as they can. Whatever maximizes their profit margins is what they'll pay for.  Given afrezza is only labeled as non-inferior, I think their cooperation would require a pretty extensive trial comparing afrezza to say, humalog, and showing that the total cost -- drug cost plus cost of treating adverse effects, complications, and so on -- of treating with afrezza is lower than the cost of humalog.  

Who among us has the talent to run a go fund me page for this?  Seems like a worthy cause.

[akemp3000]

I'm already funding Mannkind to do things like this

[peppy]

What MNKD needs to do.
In June. The ADA meeting.
This year's meeting will be held June 22-26, 2018, in the West Concourse of the Orange County Convention Center in Orlando, Florida. ... Late Breaking Abstract Submission Closes March 12, 2018 at 5:00 p.m.

Here is what I think MNKD needs to do. Once the Stat Study is released, I would like to see MNKD able to add pictures of continuing glucose monitors of Afrezza users to digital advertising.
Then I would like MNKD to add that advertising to youtube videos.

A picture is worth a thousand words, and even if it was a skip the ad, the glucose monitor and the dreamboat in 5 second glimpse? The glucose monitor with snap click inhale.

Could it be done?



afrezza.com/wp-content/uploads/Prescribinginfo.pdf

[digger]

With the increased awareness of how much photoshopping is done in ads, I imagine an awful lot of people are suspicious of any image they see nowadays.

[bradleysbest]

Dr Kendall needs to hit a grand slam at this years ADA! We need to get these dinosaurs on the Afrezza train. I think we have the right guy for the job.